Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
- PMID: 25848238
- PMCID: PMC4381895
- DOI: 10.2147/CIA.S82435
Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
Comment in
-
Authors' reply.Clin Interv Aging. 2015;10:623-4. Clin Interv Aging. 2015. PMID: 25890977 No abstract available.
Comment on
-
Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications.Clin Interv Aging. 2015 Jan 17;10:277-86. doi: 10.2147/CIA.S74102. eCollection 2015. Clin Interv Aging. 2015. PMID: 25653511 Free PMC article. Clinical Trial.
References
-
- Zhang LT, Lee SW, Park K, et al. Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications. Clin Interv Aging. 2015;10:277–286. - PMC - PubMed
-
- Sohn JT, Ding X, McCune DF, Perez DM, Murray PA. Fentanyl attenuates alpha1B-adrenoceptor-mediated pulmonary artery contraction. Anesthesiology. 2005;103:327–334. - PubMed
-
- Sato S, Hatanaka T, Yuyama H, et al. Tamsulosin potently and selectively antagonizes human recombinant α(1A/1D)-adrenoceptors: slow dissociation from the α(1A)-adrenoceptor may account for selectivity for α(1A)-adrenoceptor over α(1B)-adrenoceptor subtype. Biol Pharm Bull. 2012;35:72–77. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
